目的：采用Meta分析系统评估玻璃体腔内注射阿柏西普或雷珠单抗治疗糖尿病视网膜病变(DR)的疗效。方法：使用PubMed、MEDLINE、Web of Science、Cochrane、Nature Series、ScienceDirect、ESI等数据库进行数据检索。共纳入10项研究行玻璃体腔内注射阿柏西普或雷珠单抗治疗，1 240例糖尿病性视网膜病变(DR)患者。使用RevMan 5.3进行Meta分析。结果：合并结果显示IVA组(IVA，玻璃体腔内注射阿柏西普)黄斑中心厚度(CMT)显著降低(P<0.00001)； 与IVR组(IVR，玻璃体内注射雷珠单抗)相比，最佳矫正视力(BCVA)和视力(VA)没有明显改善。结论：研究表明IVA和IVR对治疗DR均有成效。但阿柏西普有利于改善CMT，而雷珠单抗更有利于提高BCVA或VA。

AIM: To systematically assess the effect of intravitreal injection of Aflibercept or Ranibizumab in the treatment of diabetic retinopathy(DR)by using Meta-analysis.METHODS: PubMed, MEDLINE, Web of Science, Cochrane, Nature Series, ScienceDirect, and ESI Databases were searched until May 2019. Ten studies included a total of 1 240 participants with DR had been administered in the Meta-analysis. Aflibercept or Ranibizumab via intravitreal injection. After selecting useful information, we used RevMan 5.3 to further analysis. Systematic review and Meta-analysis were used to design.RESULTS: The pooled results showed that central macular thickness(CMT)was significantly reduced(P<0.00001)in the intravitreous Aflibercept group(IVA); compared with the intravitreous Ranibizumab group(IVR), which did not greatly improve best corrected visual acuity(BCVA)and visual acuity(VA).CONCLUSION:This Meta-analysis suggests that both IVA and IVR are effective in the treatment of DR patients. Specifically, Aflibercept shows better improvements in CMT, while Ranibizumab is beneficial in increasing BCVA or VA.